Kestra Advisory Services LLC lifted its stake in Cognition Therapeutics, Inc. (NASDAQ:CGTX – Get Rating) by 150.9% during the 1st quarter, Holdings Channel reports. The firm owned 238,666 shares of the company’s stock after acquiring an additional 143,554 shares during the period. Kestra Advisory Services LLC’s holdings in Cognition Therapeutics were worth $656,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in CGTX. P.A.W. Capital Corp raised its stake in Cognition Therapeutics by 20.0% during the 1st quarter. P.A.W. Capital Corp now owns 120,000 shares of the company’s stock worth $330,000 after buying an additional 20,000 shares during the period. American Financial Group Inc. acquired a new stake in Cognition Therapeutics during the 4th quarter worth $1,296,000. Bangor Savings Bank acquired a new stake in Cognition Therapeutics during the 1st quarter worth $51,000. B. Riley Financial Inc. acquired a new stake in Cognition Therapeutics during the 4th quarter worth $195,000. Finally, AIGH Capital Management LLC acquired a new stake in Cognition Therapeutics during the 4th quarter worth $161,000. 23.40% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, LADENBURG THALM/SH SH began coverage on Cognition Therapeutics in a research note on Friday, April 22nd. They set a “buy” rating and a $10.00 price objective on the stock.
Cognition Therapeutics Trading Up 0.5 %
Cognition Therapeutics (NASDAQ:CGTX – Get Rating) last posted its quarterly earnings results on Wednesday, May 11th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.10. On average, sell-side analysts anticipate that Cognition Therapeutics, Inc. will post -1.1 earnings per share for the current year.
Cognition Therapeutics Profile
Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD).
- Get a free copy of the StockNews.com research report on Cognition Therapeutics (CGTX)
- Alibaba Group: A Huge Revenue Rebound Is Approaching
- Is There Finally Green Ahead for These 2 Cannabis Leaders?
- Ford Races Higher: Has The Stock Finally Bottomed?
- These Consumer Stocks Will Thrive And Here’s Why
- PayPal Stock is Attempting to Put in the Floor
Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.